

# Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

NCT06971939

---

Status	RECRUITING
Phase	Phase 4
Sponsor	Neurotech Pharmaceuticals
Enrollment	285 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- To be eligible to participate in this study, an individual participant must meet all the following criteria:
- Male or female adult participants who previously completed an NT-501 MacTel clinical study and:
- Arm 1: received NT-501 intraocular implant in either Phase 3 study (NTMT-03-A or NTMT-03-B)
- Arm 2: received NT-501 intraocular implant in the Phase 1 study (NTMT-01), Phase 2 study (NTMT-02), or in the substudy of the Phase 1 and Phase 2 extension study (NTMT-01/02E)
- Note: participants who received NT-501 in both eyes (ie, participated in study NTMT-02B) will be enrolled in either Arm 1 or Arm 2 based on the study in which the first NT 501 was implanted (ie, participants who received the first implant in a Phase 3 study will be enrolled in Arm 1 and those who received the first implant in the Phase 1 study or Phase 2 study will be enrolled in Arm 2).

... and 5 more (see full listing online)

### Exclusion (17)

- Participant is medically unable to comply with clinical study procedures or visits.
- Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations, and outcome assessments.
- Participant has significant corneal or media opacities in the study eye to be implanted.
- Participant has evidence of pathologic myopia in the study eye to be implanted.
- Participant has any of the following lens opacities in the study eye to be implanted: cortical opacity  $\gt$  standard 3, posterior subcapsular opacity  $\gt$  standard 2, or a nuclear opacity  $\gt$  standard 3 as measured on the Age- Related Eye Disease Study (AREDS) clinical lens grading system. Note: the participant can be reconsidered for enrollment 90 days after undergoing cataract surgery.

... and 12 more (see full listing online)

## Locations (34 total)

---

Scripps Health, La Jolla, California, United States  
Jules Stein Eye Institute/UCLA, Los Angeles, California, United States  
Stanford University School of Medicine, Palo Alto, California, United States  
... and 31 more locations

---

<https://clinicaltrials.gov/study/NCT06971939>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://ClinicalTrials.gov). Generated by [ClinicalTrialsFinder.org](https://ClinicalTrialsFinder.org).